Prognostic Role of MicroRNA-200c-141 Cluster in Various Human Solid Malignant Neoplasms

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Li, Xiao Yang ^a   Li, Hui ^a   Bu, Jie ^a   Xiong, Liang ^a   Guo, Hong Bin ^a   Liu, Li Hong ^a   Xiao, Tao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 141; MICRORNA 200C; MICRORNA; MIRN141 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; TUMOR MARKER;

BLADDER CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OBSERVATIONAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS; STOMACH CANCER; TUMOR GROWTH; BLOOD; GENETICS; NEOPLASM; PATHOLOGY;

BIOMARKERS, TUMOR; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84947927279     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/935626     Document Type: Review

References (63)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
2. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013," CA:ACancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
3. F. Bray, J.-S. Ren, E. Masuyer, and J. Ferlay, "Global estimates of cancer prevalence for 27 sites in the adult population in 2008," International Journal of Cancer, vol. 132, no. 5, pp. 1133-1145, 2013.
4. Globocan, IARC, 2012, http://globocan.iarc.fr/Pages/fact sheets cancer.aspx.
5. D. Paul, A. Kumar, A. Gajbhiye, M. K. Santra, and R. Srikanth, "Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture," BioMed Research International, vol. 2013, Article ID 783131, 16 pages, 2013.
6. G. J. Hannon and J. J. Rossi, "Unlocking the potential of the human genome with RNA interference," Nature, vol. 431, no. 7006, pp. 371-378, 2004.
7. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281-297, 2004.
8. R. C. Lee, R. L. Feinbaum, and V. Ambros, "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14," Cell, vol. 75, no. 5, pp.843-854, 1993.
9. B. Zheng, L. Liang, C. Wang et al., "MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer," Clinical Cancer Research, vol. 17, no. 24, pp. 7574-7583, 2011.
10. M. Ferracin, A. Veronese, and M. Negrini, "Micromarkers: MiRNAs in cancer diagnosis and prognosis," Expert Review of Molecular Diagnostics, vol. 10, no. 3, pp. 297-308, 2010.
11. P. Nana-Sinkamand C. M. Croce, "MicroRNAs in diagnosis and prognosis in cancer: what does the future hold?" Pharmacogenomics, vol. 11, no. 5, pp. 667-669, 2010.
12. E. Berardi, M. Pues, L. Thorrez, and M. Sampaolesi, "miRNAs in ESC differentiation," The American Journal of Physiology - Heart and Circulatory Physiology, vol. 303, no. 8, pp. H931- H939, 2012.
13. S. Roy and C. K. Sen, "miRNA in wound inflammation and angiogenesis,"Microcirculation, vol. 19, no. 3, pp. 224-232, 2012.
14. U. Burk, J. Schubert, U. Wellner et al., "A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells," The EMBO Reports, vol. 9, no. 6, pp. 582-589, 2008.
15. C. P. Bracken, P. A. Gregory, N. Kolesnikoff et al., "A doublenegative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition," Cancer Research, vol. 68, no. 19, pp. 7846-7854, 2008.
16. S.-M. Park, A. B. Gaur, E. Lengyel, and M. E. Peter, "ThemiR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2," Genes &Development, vol. 22, no. 7, pp. 894-907, 2008.
17. P. A. Gregory, A. G. Bert, E. L. Paterson et al., "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1," Nature Cell Biology, vol. 10, no. 5, pp. 593-601, 2008.
18. M. Korpal, E. S. Lee, G. Hu, and Y. Kang, "The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2," The Journal of Biological Chemistry, vol. 283, no. 22, pp. 14910-14914, 2008.
19. N. Ratert, H.-A. Meyer, M. Jung et al., "miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome,"The Journal of Molecular Diagnostics, vol. 15, no. 5, pp. 695-705, 2013.
20. M. Karaayvaz, C. Zhang, S. Liang, K. R. Shroyer, and J. Ju, "Prognostic significance of miR-205 in endometrial cancer," PLoS ONE, vol. 7, no. 4, Article ID e35158, 2012.
21. C. V. Pecot, R. Rupaimoole, D. Yang et al., "Tumour angiogenesis regulation by the miR-200 family," Nature communications, vol. 4, article 2427, 2013.
22. Q. Cao, K. Lu, S. Dai, Y. Hu, and W. Fan, "Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer," International Journal of Clinical and Experimental Pathology, vol. 7, no. 5, pp. 2392-2401, 2014.
23. H.-M. Lin, L. Castillo, K. L. Mahon et al., "Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer," British Journal of Cancer, vol. 110, no. 10, pp. 2462-2471, 2014.
24. H. Yu, B. Duan, L. Jiang et al., "Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy," American Journal of Translational Research, vol. 6, no. 1, pp. 71-77, 2013.
25. K. Tanaka, H. Miyata, M. Yamasaki et al., "Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer," Annals of Surgical Oncology, vol. 20, no. 3, pp. S607-S615, 2013.
26. T. Diaz, R. Tejero, I. Moreno et al., "Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines," Journal of Surgical Oncology, vol. 109, no. 7, pp. 676-683, 2014.
27. M. Valladares-Ayerbes, M. Reboredo, V. Medina-Villaamil et al., "Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer," Journal of TranslationalMedicine, vol. 10, no. 1, article 186, 2012.
28. S. Marchini, D. Cavalieri, R. Fruscio et al., "Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections," The Lancet Oncology, vol. 12, no. 3, pp. 273-285, 2011.
29. Y. Toiyama, K. Hur, K. Tanaka et al., "Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer," Annals of Surgery, vol. 259, no. 4, pp. 735-743, 2014.
30. H. Tang, M. Deng, Y. Tang et al., "miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression," Clinical Cancer Research, vol. 19, no. 20, pp. 5602-5612, 2013.
31. R. Tejero, A. Navarro, M. Campayo et al., "MiR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma," PLoS ONE, vol. 9, no. 7, Article ID e101899, 2014.
32. X.-G. Liu, W.-Y. Zhu, Y.-Y. Huang et al., "High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer," Medical Oncology, vol. 29, no. 2, pp. 618-626, 2012.
33. R. Hamano, H. Miyata, M. Yamasaki et al., "Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway," Clinical Cancer Research, vol. 17, no. 9, pp. 3029-3038, 2011.
34. J. Yu, K. Ohuchida, K. Mizumoto et al., "MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation,"Molecular Cancer, vol. 9, article 169, 2010.
35. M. K. Kim, S. B. Jung, J.-S. Kimet al., "Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer," Virchows Archiv, vol. 465, no. 4, pp. 463-471, 2014.
36. J. Li, X. Li, S. Ren et al., "miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type," Oncotarget, vol. 5, no. 17, pp. 7902-7916, 2014.
37. H. Cheng, L. Zhang, D. E. Cogdell et al., "Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis," PLoS ONE, vol. 6, no. 3, Article ID e17745, 2011.
38. Y. Liu, Y. Ding, J. Huang et al., "MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1," PLoS ONE, vol. 9, no. 2, Article ID e88393, 2014.
39. L. A. Selth, S. L. Townley, A. G. Bert et al., "Circulating microRNAs predict biochemical recurrence in prostate cancer patients," British Journal of Cancer, vol. 109, no. 3, pp. 641-650, 2013.
40. S. Marchini, R. Fruscio, L. Clivio et al., "Resistance to platinumbased chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer," European Journal of Cancer, vol. 49, no. 2, pp. 520-530, 2013.
41. G. Zhao, B. Wang, Y. Liu et al., "miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4,"Molecular CancerTherapeutics, vol. 12, no. 11, pp. 2569-2580, 2013.
42. R. M. Silva-Santos, P. Costa-Pinheiro, A. Luis et al., "microRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis," British Journal of Cancer, vol. 109, no. 10, pp. 2646-2653, 2013.
43. D. F. Stroup, J. A. Berlin, S. C. Morton et al., "Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group," The Journal of the American Medical Association, vol. 283, no. 15, pp. 2008-2012, 2000.
44. J. F. Tierney, L. A. Stewart, D. Ghersi, S. Burdett, and M. R. Sydes, "Practical methods for incorporating summary time-toevent data into meta-analysis," Trials, vol. 8, article 16, 2007.
45. M. K. B. Parmar, V. Torri, and L. Stewart, "Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints," Statistics in Medicine, vol. 17, no. 24, pp. 2815-2834, 1998.
46. J. Lau, J. P. A. Ioannidis, and C. H. Schmid, "Quantitative synthesis in systematic reviews," Annals of Internal Medicine, vol. 127, no. 9, pp. 820-826, 1997.
47. J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in ameta-analysis," Statistics inMedicine, vol. 21, no. 11, pp. 1539-1558, 2002.
48. N. Mantel and W. Haenszel, "Statistical aspects of the analysis of data from retrospective studies of disease," Journal of the National Cancer Institute, vol. 22, no. 4, pp. 719-748, 1959.
49. R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," Controlled Clinical Trials, vol. 7, no. 3, pp. 177-188, 1986.
50. P. T. Julian and S. G. Higgins, "Analysing data and undertaking meta-analyses," in CochraneHandbook for Systematic Reviews of Interventions, version 5.1.0, The Cochrane Library, John Wiley & Sons, Chichester, UK, 2011, http://handbook.cochrane.org/.
51. C. B. Begg and M. Mazumdar, "Operating characteristics of a rank correlation test for publication bias," Biometrics, vol. 50, no. 4, pp. 1088-1101, 1994.
52. M. Egger, G. D. Smith, M. Schneider, and C. Minder, "Bias in meta-analysis detected by a simple, graphical test," British Medical Journal, vol. 315, no. 7109, pp. 629-634, 1997.
53. L. Hong, Y. Han, S. Li et al., "The malignant phenotypeassociated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas," Expert Opinion on Biological Therapy, vol. 10, no. 12, pp. 1693-1701, 2010.
54. D.-J. Kim, S. Linnstaedt, J. Palma et al., "Plasma components affect accuracy of circulating cancer-related microRNA quantitation," The Journal of Molecular Diagnostics, vol. 14, no. 1, pp. 71-80, 2012.
55. H.-Y. Wang, J. Shen, C.-P. Jiang, and B.-R. Liu, "How to explain the contradiction of microRNA 200c expression and survival in solid tumors? A meta-analysis," Asian Pacific Journal of Cancer Prevention, vol. 15, no. 8, pp. 3687-3690, 2014.
56. F.-B. Wang, X.-Q. Yang, S. Yang, B.-C. Wang, M.-H. Feng, and J.-C. Tu, "A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients - a meta-analysis," Asian Pacific Journal of Cancer Prevention, vol. 12, no. 10, pp. 2629-2635, 2011.
57. D. Madhavan, M. Zucknick, M. Wallwiener et al., "Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers inmetastatic breast cancer," Clinical Cancer Research, vol. 18, no. 21, pp. 5972-5982, 2012.
58. H. Yazici, J. Zipprich, T. Peng et al., "Investigation of the miR16-1(C > T)+7 substitution in seven different types of cancer from three ethnic groups," Journal of Oncology, vol. 2009, Article ID 827532, 4 pages, 2009.
59. L. C. Bovell, C. Shanmugam, B.-D. K. Putcha et al., "The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer," Clinical Cancer Research, vol. 19, no. 14, pp. 3955-3965, 2013.
60. R. S. Huang, E. R. Gamazon, D. Ziliak et al., "Population differences in microRNA expression and biological implications," RNA Biology, vol. 8, no. 4, pp. 692-701, 2011.
61. S. Boccia, E. De Feo, P. Gallì, F. Gianfagna, R. Amore, and G. Ricciardi, "A systematic review evaluating the methodological aspects ofmeta-analyses of genetic association studies in cancer research," European Journal of Epidemiology, vol. 25, no. 11, pp. 765-775, 2010.
62. G. Grégoire, F. Derderian, and J. Le Lorier, "Selecting the language of the publications included in a meta-analysis: is there a Tower ofBabel bias?" Journal of Clinical Epidemiology, vol. 48, no. 1, pp. 159-163, 1995.
63. D. Moher, P. Fortin, A. R. Jadad et al., "Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews," The Lancet, vol. 347, no. 8998, pp. 363-366, 1996.